fda compounded semaglutide ban is moving to restrict mass-marketed GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified FDA moves to remove GLP-1

People with diabetes and a history of retinopathy, particularly proliferative diabetic retinopathy, should be monitored closely, as rapid glucose reduction may temporarily worsen retinal conditions

Menka Gupta, M.D., is a physician and functional medicine certified practitioner (IFMCP) in Singapore

Animal Study Findings Studies in pregnant rats and rabbits given semaglutide during organogenesis (the critical period when fetal organs develop) showed several concerning findings

Mounjaro can be even more costly

FOR RESEARCH USE ONLY

A 2025 narrative review reached comparable conclusions on the compound's positioning within the broader incretin-class research peptide spectrum (PMID 40563436)